This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Fladrafinil
Lafon-era research compound (CRL-40,941) — the bisfluoro analog of adrafinil that never made it past 1970s-80s animal pharmacology and has…
Aliases (6)
Overview
What is Fladrafinil?
Fladrafinil (CRL-40,941, fluorafinil) is a bis-fluoro analog of adrafinil and a research-chemical eugeroic. It is hydrolyzed to a fluoro-modafinil-like metabolite, reportedly with greater potency and longer duration than adrafinil.
Key Benefits
Reported wakefulness, focus, and cognitive endurance similar to or stronger than adrafinil/modafinil. Anecdotal reports of mood-flattening at higher doses. Used as a grey-market modafinil alternative.
Mechanism of Action
Prodrug metabolized to a fluorinated modafinil analog. Like modafinil, primary mechanism involves dopamine transporter inhibition, plus modulation of histamine, orexin, and norepinephrine systems for wake-promoting effects.
Pharmacokinetics
▸Brand options3 known
StatusUnscheduled in US; not approved in any jurisdiction (research-chem only)
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
once converted (assuming the prodrug hypothesis is correct), the synergy profile would be modafinil's (l-theanine, citicoline, rhodiola, bromantane, selegili…
alcohol, high-dose acetaminophen, statins, methotrexate, isoniazid, kava, comfrey, high-dose niacin. The presumed adrafinil-class hepatic load makes additive…
would unpredictably alter conversion to active metabolite. With no human PK data, the direction of the interaction is unpredictable.
assumed CYP3A4 induction (modafinil-class) reduces efficacy; same partner-relevant caveat.
(hydrafinil, flmodafinil, etc.) — combining undocumented compounds compounds the unknown safety surface.
Without characterized drug-interaction profile, "neutral" is inference, not knowledge.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety 9
Side Effects
- 1Headache — reported by users; assumed modafinil-class.
- 2Reduced appetite — reported.
- 3Insomnia / shifted sleep onset if dosed late.
- 4Anxiety / nervousness — reported less frequently than with modafinil per anecdote, though this is unreliable.
- 5Nausea, GI upset
- 6Dry mouth, increased thirst
- 7Mild HR / BP elevation
- 8Dizziness
- 9Skin irritation
When to Stop
- Stevens-Johnson Syndrome / TEN / DRESS — theoretical risk inherited from modafinil class. The watch period is unknown for fladrafinil specifically because no surveillance database exists. Treat the modafinil 1-8 week watch period as a floor, not a ceiling.
- Hepatotoxicity — adrafinil's hepatic prodrug profile was bad enough to withdraw Olmifon from the French market in 2011. Fladrafinil's structural similarity (bisfluoro adrafinil) means the same hepatic-conversion toll plausibly applies, possibly worse given the additional fluorine substitution. There is no LFT-monitoring data because there are no humans being monitored.
- Cardiovascular — assumed modafinil-class (PVCs, BP elevation). Unverified.
- Psychiatric — assumed modafinil-class (rare psychosis, mania, suicidal ideation). Unverified.
- Idiosyncratic reactions — the unknown unknowns. Any compound with no human safety surveillance has a tail of rare reactions waiting to be discovered. Modafinil's took ~10 years of post-marketing data to map out fully. Fladrafinil's have never been mapped at all.
- Weeks 1-8: rash watch (modafinil-class SJS floor — possibly longer for fladrafinil given lack of data)
- Weeks 1-12: liver enzyme watch (adrafinil-class hepatic-prodrug floor)
- Indefinite: idiosyncratic reaction watch — there is no established safety boundary
References
Fladrafinil — Wikipedia 2026
primary structural and historical reference; Lafon CRL-40,941 development history; bisfluoro adrafinil analog; never advanced past animal pharmacology.
View StudyFladrafinil — PubChem CID 91524
chemical structure, CAS, molecular reference.
View StudyAdrafinil compound file
parent comparator; hepatic prodrug pathway, Olmifon withdrawal precedent.
View StudyLafon Laboratoires CRL-series development history
context for why modafinil won the CRL-series race; other analogs (CRL-40,028 adrafinil, CRL-40,941 fladrafinil) shelved.
View StudyModafinil/Armodafinil — LiverTox NCBI Bookshelf NBK548274
modafinil hepatic safety baseline (likelihood E); the comparator that makes adrafinil-class hepatic-prodrug concerns stand out.
View StudyWADA Prohibited List 2026
modafinil banned S6 in-competition; fladrafinil likely covered by S6 catch-all language.
View StudyNootropics Encyclopedia 2026-05-05
internal reference; broader CRL-series and modafinil-family context.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.